Assessment of the P&MA potential of an in-licensing opportunity for a drug replacing surgery (Europe)
Our client, the global Pricing and Market Access function of a mid-sized pharmaceutical company, needed to evaluate the payer issues for a new in-licensing opportunity that addressed the 5 main EU markets. This product was an injectable agent for potential use in DuPuytren’s contracture and also Peyronie’s disease. The work would feed into their financial assessment of the product and their go/no-go decision.
The client challenge
Our client needed to understand for each of the two indications whether there were any significant reimbursement or funding hurdles and what price expectation was reasonable. The product represented an alternative to surgery and was complicated by the fact that different clinical settings and funding structures were used eg hospital out-patient versus office-based. Our client company’s knowledge base was low since these were new therapy areas for them. They had to have a robust view on the pricing and access issues and potential within 7 days.
How we helped
We reviewed alternative therapies to understand their effectiveness, reimbursement and usage in the major markets. We interviewed office-based and hospital surgeons in key markets to understand the impact of using drug therapy in contrast to surgery. Close attention was paid to any financial incentives that would act as barriers to the uptake of this product. Our recommendations addressed price potential and actions needed to overcome reimbursement hurdles.
Our client received our recommendations in time and was impressed by how quickly we were able to deliver a clear recommendation based on solid pricing and reimbursement insights. Our work was used to inform the value of their offer.